February 11, 2021
Study: New Prostate Cancer Test Could Avoid Unnecessary Biopsies
Building upon the foundational work conducted by research scientists at the University of Michigan, the Lynx Dx team developed MyProstateScore (MPS), the industry’s most accurate non-invasive urine test for prostate cancer. This test provides patients with an individualized risk assessment for prostate cancer by measuring urine levels of two unique cancer genes, TMPRSS2:ERG and PCA3.
MyProstateScore (MPS) has proven to eliminate unnecessary biopsies for men who have elevated PSA results but do not have the two genetic markers present. Patients with these genetic markers have a high likelihood of having prostate cancer and would need a biopsy to confirm, which can lead to a relatively high degree of complications including infection and even sepsis.